The current landscape of treatment options for venous thromboembolism: A focus on novel oral anticoagulants

Current Medical Research and Opinion

Volumn 31, Issue 2, 2015, Pages 197-210

  Hull, Russell D ^a   Gersh, Meryl H ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b AlphaBioCom   (United States)

Author keywords

Deep vein thrombosis; Direct factor Xa inhibitor; Direct thrombin inhibitor; New oral anticoagulants; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; INVESTIGATIVE PROCEDURES; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; CLASSIFICATION; CLINICAL TRIAL (TOPIC); EXPERIMENTAL THERAPY; PROCEDURES; PULMONARY EMBOLISM; SECONDARY PREVENTION; VENOUS THROMBOSIS;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY EMBOLISM; SECONDARY PREVENTION; THERAPIES, INVESTIGATIONAL; VENOUS THROMBOSIS;

EID: 84923327396     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.975786     Document Type: Review

References (75)

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419-94S
2. Nicolaides A, Hull RD, Fareed J. Diagnosis and anticoagulant treatment. Clin Appl Thromb Hemost 2013;19:187-98
3. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 Suppl):258-75S
4. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24-43S
5. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997;157:2317-21
6. Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010;137:1382-90
7. Rydberg EJ, Westfall JM, Nicholas RA. Low-molecular-weight heparin in preventing and treating DVT. Am Fam Physician 1999;59:1607-12
8. Hull RD, Marder VJ, Mah AF, et al. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med 2005;118:456-64
9. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72
10. Hull RD, Townshend G. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost 2013;110:14-22
11. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53
12. Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009;122:762-69 e3
13. Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011;124:756-65
14. Nicolaides A, Hull RD, Fareed J, et al. Prevention of postthrombotic syndrome. Clin Appl Thromb Hemost 2013;19:213-15
15. Bergqvist D. Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery. Vasc Health Risk Manag 2006;2:365-70
16. Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) 2012;25:13-15
17. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44-88S
18. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(Suppl 2):S5-12
19. Erkens PM, ten Cate H, Buller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and metaanalysis. PLoS One 2012;7:e42269
20. Xarelto (rivaroxaban) tablets. Full prescribing information. Titusville, NJ, USA: Janssen Pharmaceutical Inc., 2014. Available at: https://www.xareltohcp.-com. [Last accessed 15 June 2014]
21. Pradaxa (dabigatran etexilate mesylate). Full prescribing information. Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals Inc., 2014 Available at: http://www.pradaxapro.com. [Last accessed 15 June 2014]
22. Boehringer Ingelheim. Pradaxa gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism. Available at: http://www.boehringer-ingelheim.com/news/news-releases/press-releases/2014/06-june-2014-dabigatranetexilate.html [Last accessed 11 August 2014]
23. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
24. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
25. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5(Suppl 1):60-4
26. Samama MM. The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-compared with other anticoagulants. Thromb Res 2011;127:497-504
27. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75:476-87
28. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
29. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50: 743-53
30. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
31. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009;37:1056-64
32. Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humans. Drug Metab Dispos 2012;40:2250-5
33. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
34. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-42
35. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51:549-61
36. Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev 2013;2:358-66
37. Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects. J Thromb Haemost 2014;12(Suppl1):17
38. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495-502
39. US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inhibitors [Last accessed 11 August 2014]
40. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68
41. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
42. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338: 372-80
43. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013;76:455-66
44. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
45. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72
46. The EINSTEIN-DVT Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
47. The EINSTEIN-PE Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
48. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
49. The Hokusai-VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
50. Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study. J Thromb Haemost 2013;11:1287-94
51. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
52. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
53. Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
54. Moia M, Mantovani LG, Carpenedo M, et al. Patient preferences and willingness to pay for different options of anticoagulant therapy. Intern Emerg Med 2013;8:237-43
55. Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110:732-41
56. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-52
57. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1): S141-5
58. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011;124:1573-9
59. Escolar G, Arrelano-Rodrigo E, Reverter JC. Coagulation factor concentrates restore alterations in hemostasis induced by a high dose of apixaban: studies in vitro with circulating human blood. Blood 2012;120:2263
60. Godier A, Martin A-C, Samama C, et al. Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study. J Thromb Haemost 2013;11(Suppl s2):826
61. Halim A-B, Li Y, Stein E, Mendell J. Low concentrations of rhFVIIa or FEIBA significantly and rapidly reverse the anticoagulant effects of supratherapeutic edoxaban. Blood 2011;118:1252
62. Khoo TL, Weatherburn C, Kershaw G, et al. The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013;35:222-4
63. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24
64. Perzborn E, Heitmeier S, Laux V, Buchmü ller A. Reversal of rivaroxabaninduced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014;133:671-81
65. Kiraly A, Lyden A, Periyanayagam U, et al. Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. Am J Ther 2013;20:300-6
66. Lillo-Le Louet A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012;108:108583-5
67. Crowther M, Marthur V, Kitt M, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Blood 2013;122:3636
68. Bakhru S, Laulicht B, Jiang X, et al. A synthetic small molecule antidote for anticoagulants. Eur Heart J 2013;34:188-9, Abstract 1078
69. Laulicht B, Bakhru S, Lee C. Small molecule antidote for anticoagulants. Circulation 2012;126:A11395
70. Glund S, Stangier J, Schmol M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 2013;128:Abstract 17765
71. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4
72. Institute for Safe Medication Practices. ISMP Quarter Watch 2012 Q2. Monitoring FDA MedWatch reports. Available at: http://www.ismp.org/quarterwatch/pdfs/2012Q2.pdf [Last accessed 11 August 2014]
73. Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap between trial data and clinical practice-an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013;36:115-19
74. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397606.pdf [Last accessed 11 August 2014]
75. Kuroda Y, Hirayama C, Hotoda H, et al. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag 2013;9:593-8